LILRA2 Selectively Modulates LPS-Mediated Cytokine Production and Inhibits Phagocytosis by Monocytes by Lu, Hao K. et al.
LILRA2 Selectively Modulates LPS-Mediated Cytokine












1Inflammation and Infection Research Centre, School of Medical Sciences, Department of Pathology, University of New South Wales, United Kingdom, 2South Western
Sydney Clinical School, Liverpool Hospital, Sydney, Australia, 3Amgen Seattle, Seattle, Washington, United States of America
Abstract
The activating immunoglobulin-like receptor, subfamily A, member 2 (LILRA2) is primarily expressed on the surface of cells
of the innate immunity including monocytes, macrophages, neutrophils, basophils and eosinophils but not on lymphocytes
and NK cells. LILRA2 cross-linking on monocytes induces pro-inflammatory cytokines while inhibiting dendritic cell
differentiation and antigen presentation. A similar activating receptor, LILRA4, has been shown to modulate functions of
TLR7/9 in dendritic cells. These suggest a selective immune regulatory role for LILRAs during innate immune responses.
However, whether LILRA2 has functions distinct from other receptors of the innate immunity including Toll-like receptor
(TLR) 4 and FccRI remains unknown. Moreover, the effects of LILRA2 on TLR4 and FccRI-mediated monocyte functions are
not elucidated. Here, we show activation of monocytes via LILRA2 cross-linking selectively increased GM-CSF production but
failed to induce IL-12 and MCP-1 production that were strongly up-regulated by LPS, suggesting functions distinct from
TLR4. Interestingly, LILRA2 cross-linking on monocytes induced similar amounts of IL-6, IL-8, G-CSF and MIP-1a but lower
levels of TNFa, IL-1b, IL-10 and IFNc compared to those stimulated with LPS. Furthermore, cross-linking of LILRA2 on
monocytes significantly decreased phagocytosis of IgG-coated micro-beads and serum opsonized Escherichia coli but had
limited effect on phagocytosis of non-opsonized bacteria. Simultaneous co-stimulation of monocytes through LILRA2 and
LPS or sequential activation of monocytes through LILRA2 followed by LPS led lower levels of TNFa, IL-1b and IL-12
production compared to LPS alone, but had additive effect on levels of IL-10 and IFNc but not on IL-6. Interestingly, LILRA2
cross-linking on monocytes caused significant inhibition of TLR4 mRNA and protein, suggesting LILRA2-mediated
suppression of LPS responses might be partly via regulation of this receptor. Taken together, we provide evidence that
LILRA2-mediated activation of monocytes is significantly different to LPS and that LILRA2 selectively modulates LPS-
mediated monocyte activation and FccRI-dependent phagocytosis.
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Introduction
The leukocyte immunoglobulin-like receptor A2 (LILRA2)
belongs to a highly homologous family of activating and inhibitory
receptors constitutively expressed on the surface of leukocytes
[1,2]. LILRA2 is an activating receptor which is preferentially
expressed on monocytes, macrophages, neutrophils, eosinophils
and basophils [3–5], but not on lymphocytes or NK cells,
suggesting that this receptor may play a role in the innate immune
responses. LILRA2 contains a short cytoplasmic tail and a highly
charged transmembrane domain that associates with the common
gamma chain of the Fc receptor (FccR) and transduces activation
signals via an immunoreceptor tyrosine-based activating motif
(ITAM) [3]. Cross-linking of LILRA2 on the surface of leukocytes
recruits protein tyrosine kinase signaling molecules that lead to
cellular activation [3]. On monocytes, engagement of LILRA2
causes calcium influx and increased production of pro-inflamma-
tory cytokines [3,6,7]. Similarly, cross-linking of LILRA2 on the
surface of eosinophils and basophils causes significant degranula-
tion of these cells and increased production of pro-inflammatory
mediators and immune regulatory cytokines suggesting that it may
play a role in modulation of inflammatory responses [4,5]. This is
supported by findings of extensive expression of LILRA2 protein
on the surface of macrophages in synovial tissue of patients with
active rheumatoid arthritis [8] and on the skin of patients with
leprosy [9]. Interestingly, the level of LILRA2 expression is
significantly higher in patients with lepromatous leprosy, a disease
characterized by Th2 biased immune response leading to severe
inflammation but poor bacterial killing as compared to tuberculoid
leprosy, which is characterized by Th1 biased response with
minimal inflammation but efficient bacterial killing [9]. This
suggests that LILRA2 might be an immune modulator that may
favor Th2 immune response rather than acting as a simple
activating receptor. Moreover, LILRA2 has been shown to inhibit
dendritic cell differentiation and reduce antigen presentation to T
cells in vitro [6] suggesting a more complex functions.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33478Toll-like receptor-4 (TLR4) is expressed on monocytes and
macrophages and plays a key role in innate immune responses by
recognizing bacterial lipopolysaccharide (LPS) [10,11]. The high
affinity IgG receptor 1, FccR1 (aka CD64) is also abundantly
expressed on monocytes and is important in innate immune
responses against pathogens [12]. Aggregation of this receptor on
the surface of moncytes by antibodies and multivalent antigens
induces phagocytosis of IgG-coated antigens, causes granule
secretion and induces production of reactive oxygen species [13–
16].
This study is aimed at elucidating whether LILRA2, which is
constitutively co-expressed with TLR4 and FccR1 on the surface
of monocytes, has functions different to these receptors and/or
modulates their functions. We show that cross-linking of LILRA2
induces pro-inflammatory and immune regulatory cytokines by
monocytes that are different to cytokines induced through the
engagement of TLR4. We also show that LILRA2 strongly and
selectively modulates LPS induced activation of monocytes, partly
via regulation of TLR4 expression and inhibits IgG-dependent
particle phagocytosis. These results suggest that LILRA2 is not
only an important activating receptor in monocytes and
macrophages but also a key immune regulatory molecule capable
of fine tuning innate immune responses.
Materials and Methods
Primary antibodies and reagents
Specific mouse IgG1 monoclonal antibody (mAb) against
LILRA2 was generated in BALB/c mice by immunization with
LILR-Fc fusion protein containing the extracellular domains fused
to the Fc region of human IgG1 by L Borges at Amgen Inc
(Seattle, WA). This antibody was carefully selected for its specific
reaction to LILRA2 but not to the Fc portion of the fusion protein
or other LILR-Fc fusion proteins [17,18]. Mouse anti-CD14-PE
and FITC, CD16-Percp, CD3-PE, CD56-Percp, CD4-Percp,
CD8-APC and CD19-APC mAbs against peripheral blood
leukocyte surface markers and corresponding isotype and
flurochrome-matched IgG controls were purchased from Phar-
mingen (Mountain View, CA). Mouse anti-CD9-PE and mouse
anti-FceRI-PE were purchased from Beckman Coulter Australia
(Mount Waverly, Vic) and Serotec (Abacus ALS Australia)
respectively. FITC-conjugated anti-TLR4 mAb was purchased
from e-Biosciences (San Diego, CA). Unconjugated irrelevant
mouse IgG1-negative control and mouse IgG1 anti-MHC class I
mAbs were purchased from Sigma (Australia) and Pharmingen
respectively. Zenon mouse IgG1 labeling kit was used to directly
conjugate anti-LILRA2 with Alexa 488 (Molecular Probes Inc,
Eugene, OR). Levels of endotoxin in anti-LILRA2 cross-linking
mAb, corresponding IgG1 and anti-MHC-class I controls and
media were tested using Limulus Amebocyte Lysate (LAL) Gel
Clot method (Associates of Cape Cod Inc. Falmouth, MA, USA).
All reagents showed endotoxin levels less than the sensitivity of the
test (0.03 EU/ml).
Isolation of peripheral blood mononuclear cells (PBMC)
and monocytes
Buffy coats (100 ml) from peripheral venous blood, a by-product
of packed red cell preparation for transfusion was obtained from
healthy blood donors through the Australian Blood Services
(Australian Red Cross, Sydney). Alternatively 50 ml peripheral
venous blood was collected from 20–40 year old healthy
volunteers. The buffy coat or peripheral blood was mixed with
acid citrate dextrose and used to isolate PBMCs and polymor-
phonuclear cells (PMN) using dextran sedimentation and density
gradient centrifugation (Ficoll-Paque Plus, Amersham Biosciences,
Uppsala, Sweden) [19]. Monocytes were then negatively selected
from the freshly isolated PBMCs using magnetic beads (Monocyte
isolation kit, Miltenyi Biotec) with 9563.2% purity as confirmed
by flow cytometry using anti-CD14 mAb. High purity eosinophils
and basophils were negatively selected from fresh PMN and
PBMC respectively using magnetic beads (Miltenyi Biotec) [4,5].
This project was approved by the Australian Red Cross Blood
Services and the University of New South Wales Human Ethics
Committee. A written informed consent was obtained from each
donor.
Cell surface expression of LILRA2
Flow cytometric studies using freshly-isolated leukocytes were
performed as described [5,20]. In brief, purified leukocyte subsets
were washed with cold PBS containing 0.05% NaN3 and 1% BSA
(PAB buffer) and suspended in the same buffer at 2610
6/ml. Cells
were then incubated for 30 min at room temperature with mAbs
to LILRA2, or control mouse IgG1 (each at 5 mg/ml), washed
twice in PAB buffer and incubated on ice for 45 min with 10 ml
(10 mg/ml) FITC-conjugated F(ab9)2 goat anti-mouse IgG
[F(ab9)2-specific] (Jackson ImmunoResearch Laboratories, West
Grove, PA). Cells were fixed with 1% paraformaldehyde and
analyzed by flow cytometry. In some experiments, LILRA2-
expressing cells were characterized by co-staining with Alexa
Fluor-488-conjugated anti-LILRA2 mAb (Zenon labeling tech-
nology, Molecular probes) and a combination of saturating
amounts of flourochrome conjugated antibodies. In brief, anti-
CD14-PE, anti-FceRI-PE or combinations of CD56 Percp and
CD19-APC or CD3-PE or CD4-Percp and CD8-APC were used
to identify monocytes, basophils, NK cells, B cells and T cell
subsets in PBMC respectively. Anti-CD9-PE and anti-CD16-PE
were used to distinguish eosinophils and neutrophils in the PMN
fraction of the gradient purified leukocytes. Isotype and fluro-
chrome-matched negative control antibodies were added to cells
stained with Alexa Fluor-488 conjugated IgG1 control mAb. Cells
were fixed in 1% paraformaldehyde analysed using a four-colour
FACS Calibur Flow cytometer (BD Biosciences).
Activation of monocytes by LPS and/or LILRA2 cross-
linking in vitro
Magnetic bead purified monocytes were activated for 18 h using
10 ng/ml of LPS (Sigma-Aldrich, St Louis, MO) or by cross-
linking LILRA2 using anti-LILRA2 mAb as described [7,21]. In
brief, wells in a 96-well flat-bottom tissue culture plates (CostarH
3596, Corning, NY) were coated with 100 mL (50 mg/ml) of
F(ab9)2 goat anti-mouse IgG, Fc-specific (Jackson ImmunoRe-
search Laboratories), in PBS overnight at 4uC. Following
aspiration, 50 ml anti-LILRA2 mAb at 10 mg/ml in PBS+2.5%
fraction V BSA (Boehringer, Mannheim, Germany) was added.
Irrelevant mouse IgG1 or anti-MHC class I mAb were used as
negative controls. Plates were incubated for 2 h at 37uCi n5 %
CO2 then rinsed with 0.9% NaCl before use. Monocytes (1610
5
cells) in 200 ml of RPMI 1640 supplemented with 10 mM HEPES
(Sigma) and 0.1% BSA (Sigma) were added to each well and
incubated for 18 h at 37uC and 5% CO2. Cell-free supernatants
were collected for measurement of 18 cytokines using multiplex
assay according to manufacturer’s instruction (Bio-Plex
TM Cyto-
kine Assay, Bio-Rad Laboratories, Hercules, CA).
To assess the effects of simultaneous stimulation of monocytes
with LPS and LILRA2, LILRA2 was cross-linked using anti-
LILRA2 mAb in the presence or absence of 10 ng/ml of LPS for
18 h and cytokines measured by ELISA (R&D Systems,
Minneapolis, MN, USA). Sequential activation of LILRA2
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activation of cells through LILRA2 affects responses to LPS. In
brief, cells were cross-linked for 30 min with anti-LILRA2 coated
plates followed by further treatment with or without 10 ng/ml of
LPS for 18 h and cytokine levels in culture supernatants were then
measured by ELISA (R&D Systems). Wells coated with irrelevant
IgG1 or anti-MHC-I mAb with or without LPS were used as
controls. Effects of LILRA2 cross-linking on cytokine production
during shorter LPS treatment were assessed by pre cross-linking of
cells with anti-LILRA2 for 30 min followed by a further 2 h or 6 h
co-incubation. Selected cytokines in culture supernatants were
then measured by ELISA.
Modulation of TLR4 mRNA and protein expression in
monocytes by LILRA2 cross-linking
Expression of TLR4 mRNA was analyzed at various time-
points after LILRA2 cross-linking. In brief, 2610
5 monocytes were
washed and re-suspended in culture media, RPMI 1640
supplemented with 10 mM HEPES (Sigma) and 5% heat
inactivated autologous serum. Cells were stimulated by adding
anti-LILRA2 or IgG1 control mAb (10 mg/ml), followed by cross-
linking using goat anti-mouse Fcc-specific F (ab)2 fragment
secondary antibody (30 mg/ml, Jackson ImmunoResearch Labo-
ratories) for 6, 12, 18 and 24 h at 37uC incubator with 5% CO2.
Total RNA was extracted using Trizol (Invitrogen) from LILRA2
cross-linked monocytes and un-stimulated controls. Reverse
transcription was performed on 1 mg RNA using SuperScript III
First Strand Synthesis Supermix for qRT-PCR (Invitrogen) in a
final volume of 20 ml. cDNA was then diluted to 50 ml in RNase
and DNase free water. Aliquots (5 ml) of cDNA in a final volume of
25 ml were mixed with 16 SYBR GreenER qPCR SuperMix,
50 nM Rox dye and 200 nM of each TLR4 primer (forward 59-
ACTGCAGCTTCAACCGTATC-39; reverse 59-TAAAGGC-
TCTGCACACATCA-39) [22] and 100 nM of b-actin primers
(forward 59-CATGTACGTTGCTATCCAGGC-39; reverse 59-
CTCCTTAATGTCACGCACGAT-39) [23]. Quantitative RT-
PCR was performed on an ABI Prism 7700 Sequencer (Applied
Biosystems, Foster City, CA). The amplification program was as
follows: initialization at 50uC and 95uC for 2 minutes each
followed by 40 cycles of denaturation at 95uC for 15 seconds and
primer annealing/extension at 60uC for 60 seconds. The integrity
of amplification was verified by a dissociation curve analysis and
displayed a single melt peak for each product. The specificity of
each reaction was further confirmed by detection of a single
product of the expected size after agarose gel analysis. The same
background subtractions and threshold values for all reactions
were used to determine CT values. These standardized values
were then used to obtain mean values of multiple experiments for
statistical analysis. Results were expressed as relative ratios to the
corresponding b-actin expression.
To assess the effects of LILRA2 cross-linking on TLR4 surface
expression, cells were activated through LILRA2 for 6–48 h as
described above and stained with directly FITC conjugated anti-
TLR4 mAb and levels of expression determined by flow
cytometry.
Polystyrene-bead and bacterial phagocytosis by
monocytes after LILRA2 cross-linking
The effect of LILRA2 stimulation on phagocytosis was
determined using monocytes (2610
5) stimulated by LILRA2
cross-linking using anti-LILRA2 mAb for 12 h and 48 h followed
by a single wash using RPMI 1640. To assess polystyrene-beads
phagocytosis, 2 mm carboxylate polybeads (Polysciences, Warring-
ton, PA) were first coated with purified human IgG (Sigma) using
the BioMagH Maxi Carboxyl method according to the manufac-
turer’s instructions (Polysciences). Beads (3610
7) were then
biotinylated with Sulfo-NHS-LC-Biotin (0.3 mg/ml) as per
manufacturer’s instructions and stored at 4uC until use (Pierce,
Rockford, IL). On the day of experiment, biotinylated beads were
labeled with Streptavidin-conjugated Alexa 488 for 15 min,
washed and re-suspended in RPMI 1640 supplemented with
10 mM HEPES (Sigma) and 0.1% BSA (Sigma). Beads were
added onto LILRA2 cross-linked cells at a ratio of 10:1 and
incubated for 1 h at 37uC. Cells were washed twice in PAB, fixed
in 1% paraformaldehyde in PBS then the percentage of monocytes
that have ingested beads was determined by flow cytometry.
For bacteria phagocytosis, K12 E. coli (a gift from Prof. Hazel
Mitchell, University of New South Wales, Australia) were labeled
with pHrodo phagocytosis particle labeling kit according to the
manufacturer’s instruction (Molecular Probes, Eugene, OR).
Labeled bacteria were lyophilized at 5 mg aliquots (,2610
9
particles) and stored at 280uC until use. For subsequent
experiments, an aliquot of the labeled E. coli was thoroughly re-
suspended in 1 ml of Buffer B (Molecular Probes) and incubated
on ice for 10 min. Half (0.5 ml) of the bacteria was pelleted by
centrifugation at 5006 g for 5 minutes, then opsonized with
0.5 ml of pooled human serum from 5 healthy donors for 30 min
on ice [24] and the other half was left in Buffer B (non-opsonized).
Opsonized and non-opsonized E-coli were added onto LILRA2
stimulated monocytes at a ratio of 20:1 and incubated in a 37uC
water bath for 15 min followed by 15 min incubation on ice. Cells
were then sequentially washed with 1 ml cold Buffer B and 1 ml
Buffer C (Molecular Probes), co-stained with FITC conjugated
CD14 mAb and re-suspended in 300 ml of Buffer C. Percentages
of monocytes that ingested bacteria were then determined using
FACS Calibur flow cytometer by acquiring 10,000 events per
tube. Pre-treatment of cells with 1 mM of latrunculin, an inhibitor
of phagocytosis (Enzo Life Sciences, Farmingdale, NY) for 10 min
in RPMI1640 media prior to the addition of micro beads or E-coli
were used as controls.
Results
Surface expression of LILRA2 on peripheral blood
leukocytes
The expression pattern of LILRA2 on the surface of various
leukocytes was determined by flow cytometry. LILRA2 is
expressed on the surface of all peripheral blood monocytes,
neutrophils, basophils and eosinophils with significantly higher
levels expressed on monocytes (MFI, 58.366.1) and lowest on
eosinophils (MFI, 21.762.4) (Figs. 1A, B) (n=15). By contrast, B
cells did not express LILRA2, and expression of LILRA2 on T
cells was limited to less than 2.5% of the CD8
+ or CD4
+ cell
subsets and approximately 10% of NK cells expressed low levels of
LILRA2 (Figs. 1C, D). The level of LILRA2 expression was
significantly higher in monocytes as compared to the other
myeloid cells (Fig. 1B) and the proportion of LILRA2 positive NK
cells was significantly higher when compared to T and B cells
(Fig. 1D). These results may suggest that the primary role of
LILRA2 may be regulation of leukocytes that are mainly involved
in innate immune responses.
Activation of monocytes by either LILRA2 cross-linking
and/or LPS
We first compared the cytokine profile of LILRA2 activation in
monocytes as opposed to LPS stimulation using a multiplex
cytokine assay. Activation of monocytes by LILRA2 cross-linking
Regulation of TLR4 and FcR1 Functions by LILRA2
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significantly higher (3-fold higher) compared to LPS stimulated
cells but failed to induce IL-12 and MCP-1 production that were
strongly up-regulated by LPS (Fig. 2). Interestingly, LILRA2 cross-
linking induced similar amounts of IL-6, IL-8, G-CSF and MIP-1a
but lower levels of TNFa (3596 vs 9871 pg/ml), IL-1b (1326 vs
1802 pg/ml), IL-10 (1080 vs 1754 pg/ml) and IFNc (211 vs
370 pg/ml) compared to those stimulated with LPS (Fig. 2).
Unlike LPS, LILRA2-mediated activation of monocytes only
induced the production of IL-10, one of three immunomodulatory
cytokines (IL-10, IL-12 and IFNc) (Fig. 2). There was little or no
effect on the expression of IL-13 (Fig. 2), IL-2, IL-4, IL-5, IL-17
and Eotaxin in cells treated with LPS or LILRA2 cross-linking
(data not shown). These results suggest LILRA2 may have some
overlapping and some distinct functions from TLR4.
To assess whether LILRA2 regulates TLR4 mediated produc-
tion of selected cytokines in monocytes, LILRA2 on the surface of
cells was cross-linked in the presence of 10 ng/ml of LPS. Co-
stimulation of monocytes with LPS and LILRA2 cross-linking for
18 h produced significantly lower levels of TNFa (3171 vs
9871 pg/ml), IL-1b (75 vs 252 pg/ml) and IL-12 (112 vs
321 pg/ml) production (Fig. 3A) but had marginal additive effect
on levels of IL-10 (531 vs 400 pg/ml) and IFNc (323 vs 237 pg/
ml) and no effect on IL-6 levels (3102 vs 3595 pg/ml) production
(Fig. 3B) compared to anti-LILRA2 or LPS alone, indicating that
LILRA2 may selectively inhibit TLR4 signaling. Cross-linking of
cells with control mAbs alone showed no significant induction of
any cytokines examined nor did they alter LPS-induced cytokine
production (Fig. 3). Similarly, 30 min pre-stimulation of mono-
cytes through LILRA2 cross-linking caused significant inhibition
of subsequent LPS-induced TNFa, IL-12 and IL-1b production by
two, four, and seven-fold respectively (Fig. 4A). There was no
significant effect on subsequent LPS-induced IL-6 (3100 vs
3345 pg/ml), IL-10 (733 vs 514 pg/ml) or IFNc (388 vs
273 pg/ml) production when compared to cells pre-treated with
control IgG1 (Fig. 4B). To investigate if similar effects were
observed at a shorter incubation with LPS, levels of 3 cytokines
that showed different pattern of regulation at the 18 h time point
Figure 1. LILRA2 is differentially expressed on the surface of peripheral blood leukocytes. A. Flow cytometric analysis showing surface
expression of LILRA2 on 100% of purified monocytes, neutrophils, eosinophils and basophils (bold lines, upper panel). In contrast, only small
proportions of CD4+, CD8+ T cells or CD56+ NK cells surface expressed LILRA2 and no LILRA2 was expressed on CD19+ B cells (lower panel). B. The
mean fluorescence intensity of LILRA2 staining (level of expression) was significantly higher in monocytes as compared to neutrophils, basophils or
eosinophils. C, D. The proportion of LILRA2 expressing cells was significantly higher in NK cells as compared to T and B cells but there was no
significant difference between CD4 and CD8 T cell subsets. Isotype and fluorochrome-matched negative control antibodies were used as negative
controls (thin line). Error bars represent SEM of 15 independent experiments, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0033478.g001
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as compared to LPS. A. Activation of monocytes via LILRA2 cross-linking for 18 h significantly up-regulated the pro-inflammatory cytokines, IL-1b,
IL-6, IL-8 and TNFa, similar to cells stimulated with LPS for 18 h, albeit lower levels of TNFa production after LILRA2 cross-linking. B. Monocytes
activated through LILRA2 cross-linking also caused significant up-regulation of immune regulatory cytokines IL-10 and IFNc, a T cell chemoattractant
MIP-1a and a key cytokine in granulocyte development G-CSF at levels comparable to cells stimulated with LPS. C. In contrast, induction of GM-CSF
and inhibition of IL-12 and no effects on MCP-1 after LILRA2 cross-linking was different to cells treated with LPS that showed significant increase in IL-
12 and MCP-1 but minimal effects on GM-CSF. Neither LILRA2 cross-linking nor LPS treatment caused any significant modulation of IL-13 production.
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IL-6). LILRA2 cross-linking showed time dependent inhibition of
subsequent LPS-induced TNFa production with an average of
19.6% inhibition at 2 h and 29.7% at 6 h (Fig. 4 C, D). This is
lower than the 55% inhibition observed at 18 h time point
(Fig. 4A). Interestingly, LILRA2 cross-linking followed by LPS
treatment for 2 h had no effect but caused modest ,23% increase
in IL-10 production at 6 h as compared to the significant 42%
increase observed at 18 h time point (Fig. 4). Minimal effect was
observed on IL-6 production at both 2 h and 6 h time points
(Fig. 4). Cross-linking with anti-LILRA2 alone for 2 h did not
induce TNFa, IL-6 or IL-10 production, while there was
significant induction of all 3 cytokines at 6 h and 18 h time points
with maximum effects observed at 18 h (Fig. 4).
Regulation of TLR4 mRNA and protein expression in
monocytes after LILRA2 cross-linking
To determine whether the inhibitory effect of LILRA2 cross-
linking was due to down-regulation of LPS-recognition receptors
mainly TLR4, mRNA level of these receptor on monocytes was
assessed. LILRA2 cross-linking consistently down-regulated TLR4
mRNA expression by up to 3fold at 12, 18 and 24 hour time
points when compared to those treated with control IgG1 (Fig. 5A).
Similarly, TLR4 protein expression on the surface of LILRA2
cross-linked cells was down-regulated at 6, 12 and 18 h time points
with the highest and statistically significant effect observed 12 h
after LILRA2 cross-linking (Fig. 5B, C). Interestingly, prolonged
LILRA2 cross-linking (24–48 h) does not seem to show significant
difference in TLR4 expression to control cells (Fig. 5C).
Effects of LILRA2 cross-linking on phagocytosis of IgG
coated micro-beads and serum opsonised and non-
opsonised E coli
To assess whether LILRA2 modulates phagocytosis of IgG-
coated micro-beads or E-coli, monocytes were activated via
LILRA2 cross-linking for 12 h and 48 h. Activation of monocytes
via LILRA2 cross-linking for 12 h had no effect on phagocytosis of
IgG coated micro-beads (Fig. 6A, C). However, activation of these
cells through LILRA2 cross-linking for 48 h significantly reduced
bead phagocytosis by 30–50% as compared to cells treated with
control mAb (Fig. 6B, C). Similarly, activation of monocytes
through LILRA2 cross-linking for 48 h (Fig. 7) but not 12 h (data
not shown) has significantly inhibited phagocytosis of serum
opsonised E coli by 35–40% while having little effect (5–10%
inhibition) in uptake of non-opsonised E coli, despite the latter
being phagocytised by up to 17% of monocytes (Fig. 7). These
results indicate selective and delayed effects of LILRA2 on Fc
receptor dependent bacterial and particle phagocytosis. Treatment
of cells with a known inhibitor of phagocytosis (latrunculin)
showed minimal bead or bacterial phagocytosis (Figs. 6, 7).
Discussion
There is ample in vitro evidence [4–6] and clinical correlation
studies [8,9,25–27] that indicate LILRA2 as a key immune
regulatory molecule. For example, LILRA2 is abundantly
expressed in diseases characterized by chronic inflammation [7–
9,25–27] and in vitro cross-linking of this receptor on monocytes,
macrophages [6], eosinophils [4] and basophils [5] induces
production of several mediators involved in immune regulation.
Moreover, LILRA2 has been shown to inhibit dendritic cells
Cells treated with irrelevant IgG1 or anti-MHC class I mAb did not alter cytokine production. Cytokines in culture supernatants were assessed by
Bioplex multi-cytokine assay in quadruplicates for each experiment. Error bars represent SEM of 4 independent experiments, *p,0.05, **p,0.01,
***p,0.001 anti-LILRA2 or LPS treated as compared to IgG1 treated control cells.
doi:10.1371/journal.pone.0033478.g002
Figure 3. LPS-mediated cytokine production in monocytes is differentially modulated by concurrent activation by LILRA2 cross-
linking. A. Simultaneous activation of monocytes with LPS and LILRA2 cross-linking for 18 h significantly inhibited TNFa, IL-1b and IL-12 production
as compared to cells treated with LPS alone (4), LPS and IgG1 (5) or LPS and anti-MHC class I mAb (6). B. By contrast, this caused significant increase in
IL-10 production and had little or no effect on IL-6 and IFNc production. As expected cells treated with irrelevant IgG1 (1) or anti-MHC class I mAb (2)
alone did not induce any cytokine production. Cytokine levels in culture supernatants were analysed by Bioplex multi-cytokine assay in
quadruplicates for each experiment. Error bars represent SEM of 4 independent experiments, *p,0.05, **p,0.01 as compared to corresponding IgG1
and LPS treated controls.
doi:10.1371/journal.pone.0033478.g003
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[6]. The predominant expression LILRA2 in mono-myeloid and
NK cells shown in this study may indicate that the primary role of
this receptor may be in the regulation of innate immune responses.
Interestingly, a high level of LILRA2 is constitutively co-expressed
on monocytes with other key innate immune receptors to LPS,
TLR4 and CD14 and receptors involved in phagocytosis of
pathogens such as FccRI [14] (Fig. 1). However, whether
activation of monocytes through LILRA2 generates responses
different to LPS and/or whether LILRA2 modulates TLR4 and
FccRI-mediated monocyte activation remains unknown.
Here we show that LILRA2 cross-linking on the surface of
monocytes promotes strong induction of several pro-inflammatory
cytokines to levels comparable with those induced by LPS,
indicating overlapping effects. However, LILRA2 cross-linking,
unlike LPS activation, did not induce IL-12 or MCP-1 production
and caused production of significantly higher levels of GM-CSF
than LPS (Fig. 2). These results illustrate major differences in LPS
versus LILRA2-mediated activation of monocytes. Moreover, an
increase in the ratio of IL-10 to IL-12 (20:1) in culture
supernatants of monocytes activated through LILRA2 as com-
pared to those treated with LPS (5:1) strongly indicate responses to
LILRA2 may be biased towards Th2 type (Fig. 2) [9,28].
Furthermore, our findings showed that LILRA2 cross-linking
significantly reduced delayed Fc receptor dependent phagocytosis
of micro beads and E-coli (Figs. 6, 7) but did not affect early uptake
of particles or bacteria. These findings support the notion that
LILRA2-mediated activation of macrophages may inhibit uptake
of pathogens in chronic inflammation. These findings are in
agreement with studies showing that increased LILRA2 expression
on macrophages was strongly associated with lepromatous leprosy,
a disease characterized by increased IL-10 to IL-12 ratios and
Th2-mediated inflammatory responses together with poor bacte-
rial clearance [9]. In contrast, patients with tuberculoid leprosy
with minimal inflammation expressed low levels of LILRA2 and
demonstrated strong Th-1 responses that were effective in
mycobacterial killing [9]. Consistent with Th2 biased responses,
LILRA2 cross-linking on the surface of alveolar macrophages was
shown to dramatically reduce bactericidal activity to Mycobacterium
tuberculosis [6]. Moreover, excessive production of GM-CSF in
response to LILRA2 cross-linking may drive differentiation of
monocytes into immature dendritic cells that poorly present
antigen [29,30].
Figure 4. Activation of monocytes via LILRA2 cross-linking significantly modulates subsequent LPS-mediated production of
selected cytokines. A. Monocytes pre-activated through LILRA2 cross-linking using anti-LILRA2 mAb for 30 min followed by 18 h stimulation with
LPS produced significantly lower levels of TNFa, IL-1b and IL-12 as compared to cells treated with LPS alone (4), LPS and IgG1 (5) or LPS and anti-MHC
class I mAb (6). B. Pre -activation of monocytes via LILRA2 had additive positive effect on subsequent LPS-mediated IL-10 production but did not
affect IL-6 or IFNc production. C. At 6 h time point, significant inhibition of TNFa production, modest increase in IL-10 and no change in IL-6
production was observed in response to LPS in cells cross-linked with anti-LILRA2. D. By contrast, the effects at 2 h time point were minimal for all
three cytokines, although the inhibitory trend for TNFa was evident. Cytokine levels in culture supernatants were analysed by Bioplex multi-cytokine
assay in quadruplicates for each experiment. Error bars represent SEM of 3 independent experiments, *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0033478.g004
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to LILRA2 cross-linking may also represent a new mechanism that
encourages in situ differentiation of monocytes but avert recruit-
ment of blood-borne monocytes, thus preventing excessive
inflammation [31,32]. Potential inhibition of de novo recruitment
of monocytes by LILRA2 together with its ability to inhibit LPS-
induced pro-inflammatory cytokine production but up-regulate
suppressive cytokines strongly suggests LILRA2 is a key regulator
of the innate immune responses. Consistent with this proposal, we
showed that cross-linking of LILRA2 on the surface of monocytes
prior to LPS stimulation or simultaneous activation of cells
through LILRA2 and TLR4 caused significant inhibition of pro-
inflammatory cytokines while marginally enhancing the produc-
tion of immune regulatory cytokines (Fig. 3, 4).
We show that LILRA2 cross-linking on monocytes prior to LPS
stimulation, or simultaneous activation through LILRA2 and
TLR4, significantly reduced production of pro-inflammatory
cytokines and IL-12 (Fig. 3, 4). By contrast, LILRA2 cross-linking
had positive additive effect on the production of the anti-
inflammatory cytokine, IL-10 (Fig. 3, 4), the most significant
effects observed at later time points (Fig. 4). Although inhibition of
cellular activation by ITIM-containing inhibitory receptors is well
established [33,34], recent studies show that ITAM-containing
activating receptors including a member of LILR family (LILRA4)
[35,36], may also propagate inhibitory signals against unrelated
activating receptors [37–40]. The ITAM containing signaling
motifs of these receptors are designated as inhibitory ITAM or
ITAMi [39,41]. ITAMi exert inhibitory effects only when
stimulated in concert with unrelated activating receptor [40].
This is consistent to our results that showed that LILRA2 exerts its
inhibitory effects only in the presence of LPS that engage TLR4
(Figs. 3, 4) or IgG-coated beads and serum opsonized E-coli that
engage FccRI (Figs. 6, 7). However, the underlying mechanisms
for these inhibitory effects by ITAM-containing receptors such as
LILRA2 are not fully elucidated. Here we show that cross-linking
of LILRA2 on monocytes caused down-regulation of TLR4
mRNA and protein (Fig. 6), which may in part but not exclusively
explain the selective reduced LPS responses seen with these cells
(Figs. 3, 4). Induction of immunosuppressive mediators such as IL-
10 (Fig. 2) in response to LILRA2 cross-linking may also
Figure 5. Cross-linking of LILRA2 on monocytes caused time dependent down-regulation of TLR4 mRNA and surface protein
expression. A. Quantitative RT-PCR on mRNA extracted from purified monocytes that were activated through LILRA2 cross-linking caused down-
regulation of TLR4 mRNA expression with significant changes observed at 12, 18 and 24 h but not at 6 h time point. B. Representative flow
cytometry for the expression of TLR4 protein on the surface of monocytes activated via LILRA2 cross-linking for 6–48 hr. Dotted histograms on the
left of each plot are cells stained with isotype matched negative control mAb. C. Summary of the mean fluorescence intensity (MFI) showing
decreased expression of surface TLR4 on cells activated via LILRA2 cross-linking as compared to cells treated with IgG1 control with statistically
significant difference seen at 12 h time point. Error bars represent SEM of 5 independent experiments, *p,0.05.
doi:10.1371/journal.pone.0033478.g005
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functions. It is noteworthy that cross-linking with anti-LILRA2
alone for 2 h had little effect in the production of IL-10, while
there was significant induction at 6 h and 18 h time points (Fig. 4).
This suggests that LILRA2-induced IL-10 might contribute to the
delayed suppressive effects on LPS-mediated pro-inflammatory
cytokine production. However detailed immunological and
biochemical mechanisms for the selective LILRA2-mediated
inhibitory effects on TLR signaling requires further investigation.
These may include effects of LILRA2-cross-linking on specific
pathways that regulate production of the affected cytokines (Fig. 3,
4) [41–44] and investigation on whether LILRA2 induces other
inhibitory molecules that are known to strongly suppress TLR2
and TLR4 signaling including STAT3, SOCS3, A20 and ABIN-3
[36]. Furthermore, whether LILRA2 activation recruits inhibitory
phosphatases such as SHP-1 that can abrogate LPS-responses [45]
remains to be investigated.
Taken together we demonstrate that LILRA2 is a potent and
highly selective activating receptor as well as preferential inhibitor
of TLR4-mediated pro-inflammatory cytokine production and
FccRI-dependent phagocytosis. Therefore, effective activation of
monocytes via LILRA2 may tightly regulate their responses to
intracellular and extracellular pathogens and determine the nature
and magnitude of the innate immune responses. Despite these
Figure 6. Prolonged cross-linking of LILRA2 on monocytes significantly reduced phagocytosis of human IgG-coated polystyrene
beads. A. Schematic representation of human IgG-coated biotin-labeled polystyrene microbeads detected by streptavidine-Alexa-488 green
fluorescence (left) and representative phase contrast and fluorescence images of monocytes on the right showing uptake of variable numbers of
beads by monocytes (I, II) or none (III) after 1 h incubation with the biotin-labeled-IgG-coated beads. B. Representative Flow cytometry showing
decreased phagocytosis of human IgG-coated-biotin-labeled beads by monocytes that were activated via LILRA2 cross-linking for 48 h and incubated
with the beads for 1 hr as compared to cells treated with control IgG1. Treatment with Latrunculin, a pharmacological inhibitor of phagocytosis but
not surface attachment was used as a relevant control (right). C. Summary flow cytometric analysis of 1 hr bead phagocytosis showing significant
decrease of uptake by monocytes that were activated via LILRA2 cross-linking for 48 h but not 12 h as compared to control IgG1 treated cells. Data
from the Latrunculin treated cells indicate that less than 2% of bead positive cells might be due to non-specific attachment of beads on the cell
surface. Error bars represent SEM of 4 independent experiments, *p,0.05.
doi:10.1371/journal.pone.0033478.g006
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the significance of LILRA2 in vivo is not well established, primarily
due to lack of knowledge of its natural ligands. Thus, identification
of ligands and characterizing their interaction with LILRA2 would
further strengthen our understanding on the role of this molecule
in vivo.
Figure 7. Prolonged cross-linking of LILRA2 on monocytes significantly reduced phagocytosis of serum opsonized but not non-
opsonized E-coli.A .Schematic representation of serum opsonized pHrodo dye-labeled E-coli that fluoresce at low pH within phagocytic cells and
detected by Flow cytometry. B. Representative Flow cytometry showing phagocytosis of serum opsonized E-coli by CD14+ monocytes that were
activated via LILRA2 cross-linking, control IgG1 for 48 h or pretreated with Latrunculin for 10 min. C. Summary flow cytometric analysis of 15 min E-
coli phagocytosis showing significant decrease of uptake of opsonized but not non-opsonized bacteria by monocytes that were activated via LILRA2
cross-linking for 48 h as compared to control IgG1 treated cells. Error bars represent SEM of 3 independent experiments, *p,0.05.
doi:10.1371/journal.pone.0033478.g007
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